# Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali

> **NCT05550909** · PHASE2 · COMPLETED · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 100 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **DRUG:** Artesunate-amodiaquine combination
- **DRUG:** Primaquine Phosphate
- **DRUG:** Artemether-lumefantrine
- **DRUG:** Amodiaquine

## Key facts

- **NCT ID:** NCT05550909
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-17
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-01-26
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05550909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05550909, "Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05550909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*